Overview

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

Status:
NOT_YET_RECRUITING

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

This study uses a prospective cohort design.Subjects are randomly divided into three groups (A, B, C) before surgery. Group A gets 3 cycles of sintilimab + chemo, Group B gets 2 cycles + 1 cycle, and Group C gets 1 cycle + 2 cycles. Non-squamous NSCLC subjects receive pemetrexed/albumin paclitaxel + platinum, while squamous NSCLC subjects get albumin paclitaxel + platinum.

Phase:

PHASE3

Details

Lead Sponsor:

Tang-Du Hospital

Treatments:

Platinum Compounds
sintilimab